Affordable GLP-1s Coming to India
Generic versions of Ozempic and Wegovy could flood India as early as March 20, thanks to patent expirations—nearly 50 brands could launch, with prices dropping to $36-$48/month [https://indianexpress.com/article/health-wellness/weight-loss-drug-boom-in-india-generic-ozempic-shots-10577568]. This could dramatically increase access to GLP-1 weight-loss drugs in the region.
The expiration of the semaglutide patent on March 20, 2026, is expected to trigger a wave of generic versions from Indian pharmaceutical companies. Analysts predict that this competition could reduce drug costs by 60-70%, making the therapy significantly more affordable. Some estimate the monthly cost could fall to ₹3,000-₹4,000, a substantial decrease from the current price of ₹8,800 to ₹16,400 for Ozempic and Wegovy. Indian companies like Sun Pharma, Zydus Lifesciences, Dr. Reddy's, and Cipla are preparing to launch generic versions. Dr. Reddy's Laboratories may market their generic semaglutide injection under the brand name Obeda. With over 50 generic brands anticipated, the market is expected to shift from scarcity to abundance, sparking a price war. The Drugs Controller General of India (DCGI) has banned advertisements for GLP-1 drugs to prevent misuse and misleading claims. This ban targets direct and indirect promotions across all media, particularly those exaggerating weight loss outcomes. The Indian GLP-1 receptor agonist market is projected to grow from approximately Rs 1,000-Rs 1,200 crore in 2025 to Rs 4,500-Rs 5,000 crore by 2030.
